evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

164 questions · 165 findings · 15 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 50 · 30.3%GRADE not reported 14 · 8.5%Very low 27 · 16.4%Low 37 · 22.4%Moderate 31 · 18.8%High 6 · 3.6%

IFN‐α + PUVA vs PUVA

Improvement of quality of life · people with mycosis fungoides

The review found no eligible studies for this question.

1 finding from 1 review

Bexarotene + PUVA vs PUVA

Common adverse effects ‐ Photosensitivity (Time point of measurement: up to 16 weeks) · people with mycosis fungoides

Bexarotene + PUVA showed no clear difference in common adverse effects ‐ Photosensitivity (Time point of… compared with PUVA alone (low certainty).

1 finding from 1 review

Bexarotene + PUVA vs PUVA

Complete response · people with mycosis fungoides

Bexarotene + PUVA showed no clear difference in complete response (Time point of measurement: up to 16 weeks) compared with PUVA alone (low certainty).

1 finding from 1 review

Bexarotene + PUVA vs PUVA

Objective response rate · people with mycosis fungoides

Bexarotene + PUVA showed no clear difference in objective response rate (Time point of measurement: up to 16 weeks) compared with PUVA alone (low certainty).

1 finding from 1 review

IFN‐α + PUVA vs PUVA

Complete response · people with mycosis fungoides

IFN‐α + PUVA showed no clear difference in complete response (CR) compared with PUVA alone (low certainty).

1 finding from 1 review

Tacrolimus 0.1% vs mometasone furoate ointment

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus 0.1% vs mometasone furoate ointment

Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

The review found no eligible studies for this question.

1 finding from 1 review

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Primary: participant‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review

Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate

Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…

Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).

1 finding from 1 review